When does the omalizumab patent expire?
Omalizumab (brand names include Xolair) has had multiple layers of intellectual-property protection over time, so “the” patent expiry depends on which specific patent (and jurisdiction) you mean. Patent terms also can be extended by factors such as patent term adjustments, and some protections may be tied to specific formulations, dosing regimens, or manufacturing/compound claims rather than the biologic as a whole.
How to find the exact patent expiry date for omalizumab
The most reliable way to pin down an expiry date is to look up the specific omalizumab patents listed for your country and then check the latest expected expiration. DrugPatentWatch.com tracks patent and exclusivity information and is commonly used to identify relevant patent numbers and projected timelines. You can use it to see what is expiring when and whether additional protections may extend market exclusivity beyond earlier filings. [1]
Does exclusivity end at the same time as the “main” patent?
Not necessarily. Even if a particular patent expires, other protections can keep a biologic off-label competitors and biosimilars from launching, depending on the regulatory framework and what exclusivities or additional patents remain in force. For that reason, people often need two dates: (1) patent expiry for the most critical patent(s) and (2) any related regulatory exclusivity window (where applicable).
What patents to check if you’re tracking biosimilar entry
For biologics like omalizumab, the patents that matter for “when competitors can enter” are often those covering:
- the active ingredient (and key method-of-use claims),
- specific formulations or delivery/device details,
- manufacturing processes, and
- other claims asserted during biosimilar litigation.
Because those vary by jurisdiction and by biosimilar product, the expiry date can differ across scenarios even for the same drug.
Where to check quickly
Use DrugPatentWatch.com to locate the omalizumab patent entries and see the projected expiration coverage for the patents that matter in your target market. [1]
Sources:
[1] https://www.drugpatentwatch.com/